4.7 Article

Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer

Journal

RADIOTHERAPY AND ONCOLOGY
Volume 110, Issue 3, Pages 435-440

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2013.12.007

Keywords

Head and neck; Squamous cell carcinoma; IMRT; Dysphagia; PEG dependence

Ask authors/readers for more resources

Background and purpose: To determine if dose and/or dose-volume parameters to anatomic swallowing structures are predictive of gastrostomy tube (PEG) dependence from chemotherapy-intensity modulated radiotherapy (IMRT) in locally advanced head and neck cancer (LAHNC). Methods and materials: A retrospective study was performed on 141 consecutive patients with LAHNC (squamous cell) treated with definitive chemoIMRT with weekly concurrent carboplatin and paclitaxel. Late dysphagia was assessed by length of PEG requirement. Analysis of IMRT dose was retrospectively performed for critical swallowing structures. Results: Approximately 62% of patients required PEG, the majority placed during treatment. Mean and median time for PEG was 7.7 and 4.4 months respectively (range 1.4-43.8). Only IMRT dose to the inferior constrictor was significantly associated with length of PEG. Mean dose (of individual mean doses) was 47 Gy for prolonged PEG use versus 41 Gy for PEG <= 12 months. V-40 to the inferior constrictor also correlated with PEG > 12 months (p = 0.02) with a mean V-40 of 48% versus 41% for PEG <= 12 months. Conclusions: IMRT dose to the inferior constrictor correlated with persistent dysphagia requiring prolonged PEG use. Maintaining mean inferior constrictor dose to <= 41 Gy and V-40 to <= 41% may help minimize gastrostomy tube dependence. (c) 2014 Published by Elsevier Ireland Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials

Ting Martin Ma, Yilun Sun, Shawn Malone, Mack Roach III, David Dearnaley, Thomas M. Pisansky, Felix Y. Feng, Howard M. Sandler, Jason A. Efstathiou, Isabel Syndikus, Emma C. Hall, Alison C. Tree, Matthew R. Sydes, Claire Cruickshank, Soumyajit Roy, Michel Bolla, Philippe Maingon, Theo De Reijke, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Almudena Zapatero, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Tahmineh Romero, Michael L. Steinberg, Luca F. Valle, Matthew B. Rettig, Nicholas G. Nickols, Jonathan E. Shoag, Robert E. Reiter, Nicholas G. Zaorsky, Angela Y. Jia, Jorge A. Garcia, Daniel E. Spratt, Amar U. Kishan

Summary: The sequencing of androgen-deprivation therapy (ADT) and radiotherapy (RT) may affect the outcome of prostate cancer depending on the size of the RT field. A study found that the sequencing of ADT has a significant impact on clinical outcomes for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study

Soumyajit Roy, Scott C. Morgan, Christopher J. D. Wallis, Yilun Sun, Daniel E. Spratt, Julia Malone, Scott Grimes, Dibya Mukherjee, Amar U. Kishan, Fred Saad, Shawn Malone

Summary: Pain is an important aspect of quality-of-life in mCSPC patients, but it is uncertain whether dynamic changes in pain over time can predict OS or rPFS. This study explores the association of dynamic changes in pain scores with OS and rPFS in mCSPC patients.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Oncology

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

Ziad Bakouny, Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Chih-Yuan Hsu, Saif Alimohamed, Babar Bashir, Stephanie Berg, Mehmet A. Bilen, Daniel Bowles, Cecilia Castellano, Aakash Desai, Arielle Elkrief, Omar E. Eton, Leslie A. Fecher, Daniel Flora, Matthew D. Galsky, Margaret E. Gatti-Mays, Alicia Gesenhues, Michael J. Glover, Dharmesh Gopalakrishnan, Shilpa Gupta, Thorvardur R. Halfdanarson, Brandon Hayes-Lattin, Mohamed Hendawi, Emily Hsu, Clara Hwang, Roman Jandarov, Chinmay Jani, Douglas B. Johnson, Monika Joshi, Hina Khan, Shaheer A. Khan, Natalie Knox, Vadim S. Koshkin, Amit A. Kulkarni, Daniel H. Kwon, Sara Matar, Rana R. McKay, Sanjay Mishra, Feras A. Moria, Amanda Nizam, Nora L. Nock, Taylor K. Nonato, Justin Panasci, Lauren Pomerantz, Andrew J. Portuguese, Destie Provenzano, Matthew Puc, Yuan J. Rao, Terence D. Rhodes, Gregory J. Riely, Jacob J. Ripp, Andrea Rivera, Erika Ruiz-Garcia, Andrew L. Schmidt, Adam J. Schoenfeld, Gary K. Schwartz, Sumit A. Shah, Justin Shaya, Suki Subbiah, Lisa M. Tachiki, Matthew D. Tucker, Melissa Valdez-Reyes, Lisa B. Weissmann, Michael T. Wotman, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Yuanchu James Yang, Michael A. Thompson, Dimpy P. Shah, Jeremy L. Warner, Yu Shyr, Toni K. Choueiri, Trisha M. Wise-Draper

Summary: This cohort study found that systemic anticancer therapies, especially IO, in the context of baseline immunosuppression, were associated with severe clinical outcomes and the development of cytokine storm in patients with cancer and COVID-19.

JAMA ONCOLOGY (2023)

Article Urology & Nephrology

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Vvww Daniel, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofmanfff, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossakkk, Robert Jonesmmm, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetisp, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hrioji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin

Summary: The voting results from the 2022 Advanced Prostate Cancer Consensus Conference provide valuable insights for clinical management in areas where high-level evidence is lacking. These results can guide physicians and patients in making treatment decisions and help prioritize future research.

EUROPEAN UROLOGY (2023)

Letter Oncology

Neoadjuvant Prostate SBRT Followed by Prostatectomy

Cem Onal, Duygu Sezen, Ezgi Oymak, Yasemin Bolukbasi

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Review Oncology

Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus

Simon K. B. Spohn, Cederic Draulans, Amar U. Kishan, Daniel Spratt, Ashley Ross, Tobias Maurer, Derya Tilki, Alejandro Berlin, Pierre Blanchard, Sean Collins, Peter Bronsert, Ronald Chen, Alan Dal Pra, Gert de Meerleer, Thomas Eade, Karin Haustermans, Tobias Holscher, Stefan Hocht, Pirus Ghadjar, Elai Davicioni, Matthias Heck, Linda G. W. Kerkmeijer, Simon Kirste, Nikolaos Tselis, Phuoc T. Tran, Michael Pinkawa, Pascal Pommier, Constantinos Deltas, Nina-Sophie Schmidt-Hegemann, Thomas Wiegel, Thomas Zilli, Alison C. Tree, Xuefeng Qiu, Vedang Murthy, Jonathan I. Epstein, Christian Graztke, Xin Gao, Anca L. Grosu, Sophia C. Kamran, Constantinos Zamboglou

Summary: Current risk-stratification systems for prostate cancer do not adequately reflect the disease heterogeneity. Genomic classifiers show promise in improving risk stratification after surgery, but limited data exist for patients treated with radiation therapy or in advanced stages of the disease. A systematic review and expert survey were conducted to evaluate the role of genomic classifiers in radiation therapy and identify future research areas for personalized treatment.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Article Oncology

Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials

Paul L. Nguyen, Huei-Chung (Rebecca) Huang, Daniel E. Spratt, Elai Davicioni, Howard M. Sandler, William U. Shipley, Jason A. Efstathiou, Jeffry P. Simko, Alan Pollack, Adam P. Dicker, Mack Roach III, Seth A. Rosenthal, Kenneth L. Zeitzer, Lucas C. Mendez, Alan C. Hartford, William A. Hall, Anand B. Desai, Rachel A. Rabinovitch, Christopher A. Peters, Joseph P. Rodgers, Phuoc Tran, Felix Y. Feng

Summary: The study validates the performance of Decipher genomic classifier (GC) in pretreatment biopsy samples. The GC score is independently associated with distant metastases, prostate cancer-specific mortality, and overall survival, providing valuable prognostic information for personalized decision-making.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Article Oncology

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+Breast Cancer

Eric M. Lander, Katherine C. Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen, Yu Shyr, Vandana G. Abramson

Summary: This novel study investigates the relationship between HER2 amplification and pathologic complete response (pCR) following neoadjuvant anti-HER2 dual therapy without chemotherapy. The results show a positive association between the HER2/CEP17 FISH ratio and pCR.

ONCOLOGIST (2023)

Article Oncology

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes

Adam B. B. Weiner, Yang Liu, Alex Hakansson, Xin Zhao, James A. A. Proudfoot, Julian Ho, J. J. H. H. Zhang, Eric V. V. Li, R. Jeffrey Karnes, Robert B. B. Den, Amar U. U. Kishan, Robert E. E. Reiter, Anis A. A. Hamid, Ashely E. E. Ross, Phuoc T. T. Tran, Elai Davicioni, Daniel E. E. Spratt, Gerhardt Attard, Tamara L. L. Lotan, Melvin Lee Kiang Chua, Christopher J. J. Sweeney, Edward M. M. Schaeffer

Summary: A prostate subtyping classifier (PSC) was created by analyzing expression profiles from over 100,000 prostate tumors, identifying four subtypes with distinct biological and clinical features.

CANCER (2023)

Article Oncology

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ross Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara A. Jereczek-Fossa, Rob Jones, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel J. Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin

Summary: The APCCC 2022 addressed questions in various areas of advanced prostate cancer and provided voting results to supplement guidelines based on level 1 evidence. These results can assist clinicians, patients, research funders, and policy makers in making management decisions and identifying information gaps.

EUROPEAN JOURNAL OF CANCER (2023)

Article Urology & Nephrology

Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial

Soumyajit Roy, Yilun Sun, Scott C. Morgan, Christopher J. D. Wallis, Kevin King, Yu M. Zhou, Leah A. D'souza, Omar Azem, Adrianna E. Cueto-Marquez, Nathaniel B. Camden, Daniel E. Spratt, Amar U. Kishan, Fred Saad, Shawn Malone

Summary: This study investigated the influence of prior prostate-directed local therapy on first-line systemic therapy and survival in metastatic castrate-resistant prostate cancer (mCRPC) patients. The results showed that the efficacy and survival benefits of first-line abiraterone treatment did not significantly differ between patients who received prior local therapy and those who did not.

EUROPEAN UROLOGY (2023)

Article Endocrinology & Metabolism

Implications of metastatic stage at presentation in docetaxel naive metastatic castrate resistant prostate cancer

Soumyajit Roy, Christopher J. D. Wallis, Scott C. Morgan, Amar U. Kishan, Amy Tu Trinh Le, Julia Malone, Yilun Sun, Daniel E. Spratt, Fred Saad, Shawn Malone

Summary: This study analyzed the data from the ACIS study to determine if synchronous versus metachronous metastatic presentation is associated with survival and treatment response in docetaxel naive metastatic castrate resistant prostate cancer (mCRPC). The results showed that the stage of metastasis was not associated with disease progression, and there was no significant difference in the efficacy of treatment with docetaxel.

PROSTATE (2023)

Article Oncology

Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era

Ting Martin Ma, Felix Y. Feng, Seth A. Rosenthal, Matthew B. Rettig, Ann C. Raldow, Daniel E. Spratt, Michael Xiang, Amar U. Kishan

Summary: By comparing prostate cancer-specific mortality in patients from a real-world setting with those on a clinical trial, we found that trial patients had better outcomes, especially among Black patients, indicating significant racial disparities in the real world.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Oncology

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, S. Percy Ivy, Ranjit S. Bindra, Antonio Omuro, Patricia LoRusso

Summary: A multicenter study evaluated the efficacy of olaparib monotherapy in patients with IDH1/2-mutant gliomas. The study showed that olaparib monotherapy can produce prolonged disease stabilization in patients with grade 2/3 histology, but not in patients with grade 4 histology. This suggests potential clinical benefit of olaparib monotherapy in select populations.

CANCER RESEARCH COMMUNICATIONS (2023)

Article Biochemistry & Molecular Biology

scDemultiplex: An iterative beta-binomial model-based method for accurate demultiplexing with hashtag oligos

Li-Ching Huang, Lindsey K. Stolze, Hua-Chang Chen, Alexander Gelbard, Yu Shyr, Qi Liu, Quanhu Sheng

Summary: Single-cell sequencing is widely used for studying cellular heterogeneity, and sample multiplexing is an important technique that allows for increased capacity, decreased costs, and minimized batch effects. The crucial step in analyzing multiplexed data is demultiplexing, which assigns cells to individual samples. Accurate demultiplexing is essential to avoid misleading characterization.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2023)

Article Oncology

Low contralateral failure rate with unilateral proton beam radiotherapy for oropharyngeal squamous cell carcinoma: A multi-institutional prospective study from the proton collaborative group

Derek A. Mumaw, Allison J. Hazy, Aleksander Vayntraub, Thomas J. Quinn, Kamran Salari, John H. Chang, Noah Kalman, Sanford Katz, James Urbanic, Robert H. Press, Arpi Thukral, Henry Tsai, George E. Laramore, Jason Molitoris, Carlos Vargas, Samir H. Patel, Craig Stevens, Rohan L. Deraniyagala

Summary: This study evaluated contralateral recurrences in patients with oropharyngeal squamous cell carcinoma who received unilateral proton beam therapy. The results showed a favorable contralateral neck failure rate that was comparable to photon irradiation.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Outcomes following hypofractionated radiation therapy alone for surgically unfit early esophageal squamous cell carcinoma patients; a retrospective single center analysis

Kangpyo Kim, Dongryul Oh, Jae Myoung Noh, Yang Won Min, Hong Kwan Kim, Yong Chan Ahn

Summary: This study suggests that hypofractionated radiation therapy alone is a feasible option for early stage esophageal squamous cell carcinoma patients. Particularly, in patients with tumor length < 3 cm, this treatment scheme shows favorable local control rates with low incidence of esophageal toxicities.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy

Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang

Summary: This study analyzed the probability of hearing impairment after radiotherapy for nasopharyngeal carcinoma and developed a predictive model, providing dose limitation suggestions to improve patients' quality of life.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

FLASH radiotherapy using high-energy X-rays: Current status of PARTER platform in FLASH research

Yiwei Yang, Jianxin Wang, Feng Gao, Zhen Liu, Tangzhi Dai, Haowen Zhang, Hongyu Zhu, Tingting Wang, Dexin Xiao, Kui Zhou, Zheng Zhou, Dai Wu, Xiaobo Du, Sen Bai

Summary: This paper provides a comprehensive description of the current status of PARTER, which is the first experimental FLASH platform utilizing megavoltage X-rays. It showcases the reliable performance and stability of the dosimeters and monitors used in PARTER, as well as the satisfactory dose distribution and characteristics of the FLASH X-rays. The platform effectively meets the requirements of preclinical research on megavoltage X-ray FLASH and undergoes continuous upgrades.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation

Maria Thor, Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase, Saad Nadeem, Ellen D. Yorke, Jamie Chaft, Abraham J. Wu, Michael Offin, Charles B. Simone Ii, Isabel Preeshagul, Daphna Y. Gelblum, Daniel Gomez, Joseph O. Deasy, Andreas Rimner

Summary: The purpose of this study was to identify predictors of disease progression in early-stage non-small cell lung cancer (NSCLC) patients after receiving definitive stereotactic body radiation therapy (SBRT). The results showed that tumor diameter and SUVmax were the most frequently reported features associated with progression/survival, and a re-fitted model including these two features had the best performance.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

A comprehensive predictive model for radiation-induced brain injury in risk stratification and personalized radiotherapy of nasopharyngeal carcinoma

Yong-Qiao He, Tong-Min Wang, Da-Wei Yang, Wen-Qiong Xue, Chang-Mi Deng, Dan-Hua Li, Wen-Li Zhang, Ying Liao, Ruo-Wen Xiao, Lu-Ting Luo, Hua Diao, Xia-Ting Tong, Yan-Xia Wu, Xue-Yin Chen, Jiang-Bo Zhang, Ting Zhou, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Shao-Dan Zhang, Ye-Zhu Hu, Guan-Qun Zhou, Jun Ma, Ying Sun, Wei-Hua Jia

Summary: In this study, researchers aimed to establish a predictive model for radiation-induced brain injury (RBI) in nasopharyngeal carcinoma (NPC) patients by incorporating clinical factors and newly developed genetic variants. They conducted a large-scale retrospective study and a genome-wide association study to develop a polygenic risk score (PRS) for RBI risk prediction. The results showed that the PRS, combined with clinical factors, improved the accuracy of RBI risk stratification and suggested personalized radiotherapy.

RADIOTHERAPY AND ONCOLOGY (2024)

Review Oncology

Brachytherapy is an effective and safe salvage option for re-irradiation in recurrent glioblastoma (rGBM): A systematic review

Xiaoyong Xiang, Zhe Ji, Jing Jin

Summary: A review of studies suggests that brachytherapy as a salvage therapy for recurrent glioblastoma shows acceptable safety and good post-treatment clinical efficacy for selected patients.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts

M. Berbee, C. T. Muijs, F. E. M. Voncken, L. Wee, M. Sosef, B. van Etten, J. W. van Sandick, F. A. R. M. Warmerdam, J. J. de Haan, E. Oldehinkel, J. M. van Dieren, L. Boersma, J. A. Langendijk, A. van der Schaaf, J. B. Reitsma, E. Schuit

Summary: This study externally validated a model for predicting 2-year total mortality in lung cancer patients in esophageal cancer patients. The intercept and/or slope of the original model needed adjustment to achieve good performance in esophageal cancer patients.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Nine years of plan of the day for cervical cancer: Plan library remains effective compared to fully online-adaptive techniques

Dominique Reijtenbagh, Jeremy Godart, Joan Penninkhof, Sandra Quint, Andras Zolnay, Jan-Willem Mens, Mischa Hoogeman

Summary: This study compared the performance of the current PotD strategy with non-adaptive and fully online-adaptive techniques in the treatment of cervical cancer patients. The findings show that the PotD protocol is effective in improving normal tissue sparing compared to no adaptation, while fully online-adaptive approaches can further reduce target volume but come with a more complex workflow.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Prediction of radiation pneumonitis using the effective α/β of lungs and heart in NSCLC patients treated with proton beam therapy

Albrecht Weiss, Steffen Loeck, Ting Xu, Zhongxing Liao, Aswin L. Hoffmann, Esther G. C. Troost

Summary: Traditional models for predicting radiation pneumonitis may not be applicable to non-small cell lung cancer patients treated with passively-scattered proton therapy. The use of effective alpha/beta parameter can predict the occurrence of radiation pneumonitis in these patients.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Primer shot fractionation with an early treatment break is theoretically superior to consecutive weekday fractionation schemes for early-stage non-small cell lung cancer

Z. A. R. Gouw, J. Jeong, A. Rimner, N. Y. Lee, A. Jackson, A. Fu, J-j. Sonke, J. O. Deasy

Summary: This study investigates the effectiveness of non-uniform fractionation schedules in radiotherapy for early-stage non-small cell lung cancer. Through modeling, optimized schedules are proposed to minimize local failures and toxicity risk. The results suggest that non-standard primer shot fractionation can reduce hypoxia-induced radioresistance and improve treatment outcomes.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Curative carbon ion radiotherapy in a head and neck mucosal melanoma series: Facing the future within multidisciplinarity

Sara Ronchi, Alessandro Cicchetti, Maria Bonora, Rossana Ingargiola, Anna Maria Camarda, Stefania Russo, Sara Imparato, Paolo Castelnuovo, Ernesto Pasquini, Piero Nicolai, Mohssen Ansarin, Michele Del Vecchio, Marco Benazzo, Ester Orlandi, Barbara Vischioni

Summary: This study evaluates the efficacy and toxicity of carbon ion radiotherapy (CIRT) in locally advanced head and neck mucosal melanoma patients. The results show that CIRT is safe and effective in treating the local region, and immunotherapy after relapse can improve overall survival. However, further prospective trials are needed to assess the role of targeted/immune- systemic therapy in this disease.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

The rise of negative portrayals of radiation oncology: A textual analysis of media news

Dominik Wawrzuta, Justyna Klejdysz, Marzanna Chojnacka

Summary: This study analyzed articles about radiation oncology published in The New York Times since its inception in 1851, and identified changes in media sentiment and prevalent themes related to radiotherapy. The findings suggest an increasing negative sentiment in media coverage towards radiotherapy, with a shift towards reporting treatment errors, toxicity, and ineffectiveness.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses

Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin

Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Meta-analysis of 5-day preoperative radiotherapy for soft tissue sarcoma (5D-PREORTS)

Fabio L. Cury, Gustavo A. Viani, Andre G. Gouveia, Camila V. S. Freire, Gabriel de A. Grisi, Fabio Y. Moraes

Summary: In limb-sparing treatment of soft tissue sarcoma patients, a 5-day course of preoperative radiotherapy results in high local control and favorable R0 margins, with acceptable complication rates, particularly for patients receiving higher biological equivalent doses.

RADIOTHERAPY AND ONCOLOGY (2024)